238 related articles for article (PubMed ID: 36347552)
1. The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations.
Ye C; Ho JN; Kim DH; Song SH; Kim H; Lee H; Jeong SJ; Hong SK; Byun SS; Ahn H; Hwang SI; Lee HJ; Lee S
Investig Clin Urol; 2022 Nov; 63(6):631-638. PubMed ID: 36347552
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
[TBL] [Abstract][Full Text] [Related]
3. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
4. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
6. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
7. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
[TBL] [Abstract][Full Text] [Related]
9. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
[TBL] [Abstract][Full Text] [Related]
10. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
11. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population.
Hsieh PF; Li WJ; Lin WC; Chang H; Chang CH; Huang CP; Yang CR; Chen WC; Chang YH; Wu HC
World J Urol; 2020 May; 38(5):1207-1214. PubMed ID: 31440806
[TBL] [Abstract][Full Text] [Related]
12. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
[TBL] [Abstract][Full Text] [Related]
13. The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.
Zhang X; Hong H; Liang D
Cancer Imaging; 2022 Oct; 22(1):60. PubMed ID: 36258247
[TBL] [Abstract][Full Text] [Related]
14. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
15. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
Haack M; Miksch V; Tian Z; Duwe G; Thomas A; Borkowetz A; Stroh K; Thomas C; Haferkamp A; Höfner T; Boehm K
World J Urol; 2022 Dec; 40(12):2947-2954. PubMed ID: 36318314
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy.
Busetto GM; Del Giudice F; Maggi M; De Marco F; Porreca A; Sperduti I; Magliocca FM; Salciccia S; Chung BI; De Berardinis E; Sciarra A
World J Urol; 2021 Jun; 39(6):1869-1877. PubMed ID: 32681273
[TBL] [Abstract][Full Text] [Related]
17. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of multifactorial diagnosis in prostate biopsy.
Li J; Wang K; Li S; Wu P; Wang X; He Y; Tang W
Prostate; 2023 Nov; 83(15):1494-1503. PubMed ID: 37545333
[TBL] [Abstract][Full Text] [Related]
19. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
[TBL] [Abstract][Full Text] [Related]
20. Prospective analysis of clinically significant prostate cancer detection with [
Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
